CSANZ 2019

Sponsored Breakfast Symposia

Sponsored Breakfast sessions will be held from 0730 - 0815hrs on Friday 9 August,
with breakfast available from 0715-0730hrs. RSVP your breakfast attendance when you register.

Cardiovascular effects of diabetes medications: Lessons learned from cardiovascular outcomes trials

Speaker: Professor Darren K. McGuire

Since 2008, drugs for diabetes have been required to undergo formal cardiovascular safety assessment in clinical trials. In response, numerous trials of diabetes medications have now been completed with numerous others ongoing. The accumulated data from completed trials will be summarized and the impact of these data on contemporary professional society recommendations and their impact on cardiovascular clinical care will be reviewed with specific focus on recommendations for cardiologists with regard to prescribing selected medications for cardiovascular risk mitigation.

Breakfast Session details to be confirmed

Breakfast Session details to be confirmed

 

FH reality check: is your perception patient-centred?

Speakers: Karam Kostner (QLD) and Stephen Nicholls (VIC) 

Chair: Gerald Watts (WA)

Safety of newer diabetes medications – practical considerations for cardiologists

Speakers: A/Prof John Amerena and Professor Sophia Zoungas

The prevalence of type 2 diabetes has become a global emergency despite increased awareness of the need for diabetes prevention however this knowledge is not translated into action that effectively reduces diabetes prevalence. Safe management of patients with diabetes by utilising different medications is important to physicians and patients.

Previous concerns around the safety of several classes of diabetes medications have now been addressed through numerous studies providing reassurance of the safety profile of different diabetes management medications.

Please join us for an information session on the practical considerations of newer diabetes medications for your patients.

No second chances – frontiers in preventative medicine

Chair: Tom Marwick, Director and Chief Executive of the Baker Heart and Diabetes Institute

Speakers: Tom Marwick,, Martin Cowie, Professor of Cardiology, Imperial College London and Honorary Consultant Cardiologist, Royal Brompton Hospital, London, UK, and Chris Hammett, Interventional Cardiologist, Royal Brisbane and Women’s Hospital

“In just 7 days, about 10% of people who have a stroke will have another”.1 There is a significant unmet need in high risk patients with cardiovascular disease resulting in disabling stroke or mortality.2 These patients may not have a second chance and there is an urgency to intervene. Join us as we explore frontiers in preventative medicine and challenge the paradigm to provide tailored protection for patients with cardiovascular disease.

References:
1. Coull AJ et al.Population based study of early risk of stroke after transient ischaemic attack or minor stroke: implications for public education and organisation of services. BMJ. 2004;328:326.
2. No Second Chances. The Baker Heart and Diabetes Institute. February 2019

Impella percutaneous LVAD: Global best practice and cost-effectiveness in an Australian setting 

Speakers: Dr William Lombardi, University of Washington Medical Center, USA and Dr Sidney Lo from Liverpool Hospital, Sydney, Australia

Dr. William Lombardi from University of Washington Medical Center, USA will share the principles and best practice of Impella Percutaneous LVAD. Dr. Sidney Lo from Liverpool Hospital, Sydney will share Protected PCI cost-effectiveness and outcomes insight based on Liverpool Hospital Case Series, a single-center experience in using both VA-ECMO and Impella Percutaneous LVAD in an Australian setting. Both Impella and Veno-Arterial extracorporeal membranous oxygenation(VA-ECMO) provide cardiac output support during high-risk PCI (HR-PCI).  This analysis compared the clinical and economic impact for high-risk patients undergoing Protected PCI for the total episode-of-care expenditure reflecting the patient comorbidities, consumable costs, hospital and ICU length-of-stays and management of any device-related complications.

Breakfast Session details to be confirmed

Overcoming the challenges of treating HeFH with available PCSK9 inhibitors

Heterozygous familial hypercholesterolaemia (HeFH) is the most common autosomal dominant genetic disorder characterised by elevated levels of LDL-C1.

An LDL-C < 1.8 mmol/L is recommended for patients with HeFH who are at very high CV risk1, however up to 80% of these patients do not achieve an LDL-C level of Treatment with PCSK9 inhibitors in addition to lipid lowering therapy enables more patients with HeFH and high CV risk to achieve specific LDL-C goals4, 5,6 but access to PCSK9i therapy is highly dependent on successful HeFH diagnosis and optimisation of background agents. This symposium addresses such challenges in identifying high CV risk HeFH patients and navigates pathways for implementation of PCSK9i therapy in those with high CV risk.

References:
1. Nordestgaard BG et al. Familial hypercholesterolaemia is underdiagnosed and undertreated in the general population: guidance for clinicians to prevent coronary heart disease: consensus statement of the European Atherosclerosis Society. EurHeart J 2013; 34: 3478–3490a.
2. Huijgen R et al. Two years after molecular diagnosis of familial hypercholesterolemia: majority on cholesterol-lowering treatment but a minority reaches treatment goal. PLoS One 2010; 5: e9220.
3. Pijlman AH et al. Evaluation of cholesterol lowering treatment of patients with familial hypercholesterolemia: a large crosssectional study in the Netherlands. Atherosclerosis 2010;209:189–194.
4. Kastelein JJP et al. ODYSSEY FH I and FH II: 78 week results with alirocumab treatment in 735 patients with heterozygous familial hypercholesterolaemia. Eur Heart J 2015; DOI:10.1093/eurheartj/ehv370
5. Robinson JG et al. Efficacy and Safety of Alirocumab in Reducing Lipids and Cardiovascular Events. NEJM 2015; DOI: 10.1056/NEJMoa1501031
6. Raal et al. PCSK9 inhibition with evolocumab (AMG 145) in heterozygous familial hypercholesterolaemia (RUTHERFORD-2): a randomised, double-blind, placebo-controlled trial. The Lancet. 2015; DOI: 10.1016/S0140-6736(14)61399-4